ArticleMolecular oncology2025
Transcriptome-wide analysis of circRNA and RBP profiles and their molecular relevance for GBM.
Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Hsa_circ_0000711 can serve as a novel biomarker for primary biliary cholangitis by promoting disease progression through the regulation of miR-185-5p and NFATc3.RNA biology · 2026Article
- A Tailored Workflow for Circular RNA Enrichment and Analysis from Human Whole Blood.Biomolecules · 2026Article
- Circular RNAs in Neurons: From Transport to Function.Non-coding RNA · 2026Review
- Circular RNA dynamics in breast-to-brain metastatic cascade.BMC biology · 2026Article
- UCMSC-derived exosomal circDLGAP4 enhances HFF-1 cell proliferation and migration by promoting ZNF217 promoter H3K27 acetylation.Molecular genetics and genomics : MGG · 2026Article
- Diamond Nanoparticles Suppress Migration of T98G Glioblastoma Cells by Targeting ECM-Integrin Interactions and Intracellular Signaling, Leading to Extensive Proteome Alterations.Nanotechnology, science and applications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most aggressive and lethal type of glioma, characterized by aberrant expression of noncoding RNAs including circular RNAs (circRNAs). CircRNAs may impact cellular processes by interacting with other molecules-like RNA-binding proteins (RBPs). The diagnostic value of circRNA and circRNA/RBP complexes is still largely unknown. To explore circRNA and RBP transcript expression in GBM, we performed and further analyzed RNA-seq data from GBM patients' primary and recurrent tumor samples. We identified circRNAs differentially expressed in primary tumors, the circRNA progression markers in recurrent GBM samples, and the expression profile of RBP genes. Furthermore, we demonstrated the clinical potential of circRNAs and RBPs in GBM and proposed them as stratification markers in de novo assembled tumor subtypes. Additionally, we experimentally validated the subcellular localization of select circRNAs and their interactions with FUS. Subsequently, we showed that circARID1A may play a role in promoting GBM cell proliferation. Overall, we described circRNA-RBP interactions that could play a regulatory role in gliomagenesis and GBM progression and provided a list of molecular players in GBM for further extensive studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.